Verastem (VSTM) news
Recent news
Trading halted: (VSTM) Due to limit-up limit-down trading pause
AInvest Wire · 4h agoVerastem shares fall 2.3%
AInvest Wire · 4h agoVerastem - Estimates Q3 2026 net product revenue at $23.9 mln-$24.10 mln - SEC filing
Verastem Inc. has provided an updated revenue forecast for the third quarter of 2026, estimating net product revenue in the range of $23.9 million to $24.10 million, according to a recent SEC filing [1]. This guidance reflects the company’s ongoing performance in commercializing its therapeutic…
AInvest Wire · 7h agoVeraSTEM Oncology names Michael Bailey CEO, effective Jan. 1
VeraSTEM Oncology has announced that Michael Bailey will assume the role of Chief Executive Officer, effective January 1, 2027[1]. Bailey succeeds the current CEO, who will transition to a senior advisory role within the company. The board of directors cited biopharmaceutical leadership and…
AInvest Wire · 7h agoVeraSTEM - Net proceeds to fund clinical development including VS-7375 program and corporate purposes
Verastem Oncology (Nasdaq: VSTM) has announced plans to utilize net proceeds from recent financing activities to advance its clinical development programs, with a primary focus on its VS-7375 oral KRAS G12D (ON/OFF) inhibitor. The company is currently conducting the Phase 1/2 TARGET-D 101 trial,…
AInvest Wire · 7h agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.